Q4 2025 LeMaitre Vascular Inc Earnings Call Transcript
Key Points
- LeMaitre Vascular Inc (LMAT) reported a strong Q4 with 16% sales growth, a 71.7% gross margin, and 47% operating income growth.
- The company saw significant growth in specific product lines: grafts up 27%, valvulomes up 20%, and shunts up 18%.
- International sales are expanding, with autograft sales expected to contribute $6 million in sales growth for 2026.
- The company is expanding its direct sales model, planning to go direct in Poland and other European countries, enhancing market penetration.
- LeMaitre Vascular Inc (LMAT) has a strong cash position with $359 million in cash and securities, supporting potential M&A activities and share repurchase programs.
- The company experienced a cyber incident in January 2026, which affected certain systems and data, though it claims minimal disruption.
- There is a potential headwind from the manufacturing transfer of the Restore Flow business from Chicago to Burlington, which may impact margins in 2026.
- The company faces challenges in the Chinese market, with limited impact from the Xenosure cardiac approval despite previous efforts.
- The carotid artery stenting business may face challenges due to the CREST 2 trial results, which could impact future sales.
- LeMaitre Vascular Inc (LMAT) is cautious about providing detailed quarterly guidance for specific product lines, reflecting uncertainty in market dynamics.
Welcome to the Lamate Vascular Q4 2025 financial results conference call.
As a reminder, today's call is being recorded.
At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of Lama Vascular. Please go ahead, sir.
Thank you. Good afternoon and thank you for joining us on our Q4 2025 conference call.
With me on today's call is our CEO George LeMay, and our President, Dave Roberts.
Before we begin, I'll read our safe harbor statement.
Today we'll be making some forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1,995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will TRY to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
